SANT 2

SANT 2 is a potent Hh-signaling pathway antagonist. SANT 2 interferes with the expression of Gli1. SANT 2 causes developmental delay in medaka embryos. SANT 2 has the potential for the research of several malignancies including Gorlin syndrome (a disorder predisposing to basal cell carcinoma, medulloblastoma and rhabdomyosarcoma), prostate, pancreatic and breast cancers[1][2].

Product Specifications

CAS Number

[329196-48-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Gli; Hedgehog

Type

Reference compound

Related Pathways

Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/sant-2.html

Purity

99.41

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

ClC1=CC=C(NC(C2=CC(OCC)=C(OCC)C(OCC)=C2)=O)C=C1C3=NC4=CC=CC=C4N3

Molecular Formula

C26H26ClN3O4

Molecular Weight

479.96

Precautions

H302, H315, H319

References & Citations

[1]Büttner A, et al. Synthesis and biological evaluation of SANT-2 and analogues as inhibitors of the hedgehog signaling pathway. Bioorg Med Chem. 2009 Jul 15;17 (14) :4943-54.|[2]Rominger CM, et al. Evidence for allosteric interactions of antagonist binding to the smoothened receptor. J Pharmacol Exp Ther. 2009 Jun;329 (3) :995-1005.